经皮射频消融治疗原发性肝癌——附55例随访结果

PERCUTANEOUS RADIOFREQUENCY ABLATION TREATMENT OF UNRESECTABLE PRIMARY HEPATIC CANCER: FOLLOW-UP RESULTS IN 55 PATIENTS

采用射频消融方法(RFA)治疗原发性肝癌 (PHC)患者 5 5例 ,治疗后每 3～ 6个月复查腹部B超和 (或 )CT ,5 5例患者平均随访 2 3 7个月。结果 14例存活 ,41例死亡 ;第 1、2、3年累积生存率分别为 78 2 %、5 6 4%和 2 5 5 % ;死亡与肿块数量无明显相关 (P >0 0 5 ) ,但死亡组的肿块直径 ( 7 3± 2 7cm)明显大于存活组 ( 4 3± 2 2cm ,P <0 0 1) ;RFA治疗前接受过其他非手术治疗者的病死率( 86 9% )与未接受过其他非手术治疗者( 65 6% )比较无明显差异 (P >0 0 5 ) ;14例存活患者中 ,10例 ( 71 4% )无瘤存活。

The follow-up results of percutaneous radiofrequency ablation(RFA) treatment of unresectable primary hepatic cancer(PHC) in 55 patients were reported in this paper. The B ultrasound and/or computed tomography were performed every 3-6 months after RFA treatment. With a median follow-up of 23.7 months in 55 patients, 14 survived and 41 died. The cumulative survival rates at 1,2 and 3 years were 78.2%?56.4% and 25.5%,respectively. Death was not significantly related to the number of PHC nodules(P>0.05). The median diameter of the nodules in survival group was smaller (4.3±2.2cm)than that in death group(7.3±2.7cm, P<0.01). There was no significant difference in death rates between patients subjected to nonsurgical treatment and patients not subjected to nonsurgical treatment before RFA(86.9% vs 65.6%, P>0.05). Ten of 14 survived patients remained clinical free of tumor. In conclusion, RFA could extend survival time for patients with unresectable PHC.